Tdam USA Inc. maintained its position in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,036 shares of the pharmaceutical company’s stock at the end of the second quarter. Tdam USA Inc.’s holdings in GlaxoSmithKline PLC were worth $218,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Carroll Financial Associates Inc. increased its position in shares of GlaxoSmithKline PLC by 0.4% in the second quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock worth $374,000 after buying an additional 35 shares in the last quarter. First National Bank of Omaha boosted its stake in shares of GlaxoSmithKline PLC by 0.3% in the second quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock valued at $827,000 after buying an additional 57 shares during the last quarter. Pekin Singer Strauss Asset Management IL boosted its stake in shares of GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 60 shares during the last quarter. Baystate Wealth Management LLC boosted its stake in shares of GlaxoSmithKline PLC by 1.4% in the second quarter. Baystate Wealth Management LLC now owns 5,520 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 75 shares during the last quarter. Finally, Investment Partners Ltd. OH ADV boosted its stake in shares of GlaxoSmithKline PLC by 0.8% in the second quarter. Investment Partners Ltd. OH ADV now owns 9,491 shares of the pharmaceutical company’s stock valued at $409,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 8.96% of the company’s stock.

Shares of GlaxoSmithKline PLC (GSK) opened at 38.90 on Friday. The company’s 50-day moving average is $41.99 and its 200-day moving average is $41.84. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59. The stock has a market cap of $95.07 billion, a PE ratio of 37.62 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 5.05%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is currently 197.00%.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline PLC (NYSE:GSK) Stake Held by Tdam USA Inc.” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/glaxosmithkline-plc-nysegsk-stake-held-by-tdam-usa-inc.html.

Several brokerages have recently weighed in on GSK. Citigroup Inc. cut shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. ValuEngine cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, May 31st. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. GlaxoSmithKline PLC has an average rating of “Hold” and an average price target of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.